Companies · Other Technology

RxLive Inc.

ST. PETERSBURG · Other Technology

Diligence memoA one-page analyst read on RxLive Inc. — recommendation, valuation, rhythm, risks.
$10.1M
Total raised · real
5
Rounds
3.1×
Latest step-up
Top 28%
Sector rank · raised
Series A
Latest stage · inferred · Fri Apr 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

RxLive Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.36× the median modeled value of Series A Other Technology companies in 2022–2024 (1325 peers) — value vs value, same stage and era.
  • Within the normal band (136% of peer median) for its niche.
Dormant
  • Last raise 4.2 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Technology

RxLive Inc. is one of 21292 Other Technology companies tracked from ST. PETERSBURG. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2018
Year incorporated
2022-04-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2018-06-21 Raised $600K (real) Modeled valuation $25M (est)$600K$25MPre-Seed2018Pre-Seed · 2019-05-15 Raised $850K (real) Modeled valuation $36M (est)$850K$36MPre-Seed2019Seed · 2020-07-31 Raised $2.0M (real) Modeled valuation $65M (est)$2.0M$65MSeed2020Seed · 2022-04-08 Raised $1.6M (real) Modeled valuation $24M (est)$1.6M$24MSeed2022Series A · 2022-04-08 Raised $5.0M (real) Modeled valuation $68M (est)$5.0M$68MSeries A2022+$850K+$2.0M+$1.6M+$5.0MCumulative $10M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$600K · 2018
Pre-Seed extension$850K · 2019
Seed$2.0M · 2020
Seed extension$1.6M · 2022
Series A$5.0M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$68.5M
Base estimate est.
$6.7M
Conservative case
$247.5M
Upside case
$23.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $25.4M · 2018-06-212018Pre-Seed · modeled $36.0M · 2019-05-15Seed · modeled $65.4M · 2020-07-31Seed · modeled $24.1M · 2022-04-08Series A · modeled $68.5M · 2022-04-082022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
29% low · 74% high
1.50×/yr
Annual markup
1.89×/yr upside case
4.2 yr
Elapsed time used
4.2 yr actual, capped for stale marks
technology
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$2.7M/yr
Capital velocity
8.0 yr
On record since
2018
First round
5
Rounds on file
How it compares to the market

Benchmarked against 21292 companies in Other Technology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.2× above median
This company$10.1M
Sector median$3.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$5.0M
Sector median$5.8M
Modeled value — vs sector median (estimate, all stages) 1.8× above median
This company$68.5M
Sector median$37.3M

Raised more than 73% of sector peers (real $). Modeled value above 64% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #435 of 1,325.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Phylum, Inc. · Series A Raised $15.0M · modeled $222.2M (est)Keon Foundation Ltd. · Series A Raised $15.0M · modeled $211.9M (est)Remoteam Inc. · Series A Raised $14.3M · modeled $209.5M (est)MultiSafe, Inc. · Series A Raised $17.3M · modeled $208.6M (est)Careerian Inc. · Series A Raised $20.3M · modeled $203.8M (est)Continu Inc. · Series A Raised $13.5M · modeled $202.4M (est)Devron Corp · Series A Raised $16.8M · modeled $201.5M (est)RISC Zero, Inc. · Series A Raised $14.4M · modeled $199.5M (est)Pentagon Port LLC · Series A Raised $15.0M · modeled $198.7M (est)Amnic Inc. · Series A Raised $14.0M · modeled $198.2M (est)Intensivate Inc · Series A Raised $14.7M · modeled $190.3M (est)Ws Holdco, Pbc · Series A Raised $14.8M · modeled $188.2M (est)RxLive Inc. (this company) Raised $10.1M · modeled $68.5M (est)RxLive Inc.
CompanyStageRaised · realValue · estvs peer med.
Phylum, Inc.Series A$15.0M$222.2M4.42×
Keon Foundation Ltd.Series A$15.0M$211.9M4.22×
Remoteam Inc.Series A$14.3M$209.5M4.17×
MultiSafe, Inc.Series A$17.3M$208.6M4.15×
Careerian Inc.Series A$20.3M$203.8M4.06×
Continu Inc.Series A$13.5M$202.4M4.03×
Devron CorpSeries A$16.8M$201.5M4.01×
RISC Zero, Inc.Series A$14.4M$199.5M3.97×
Pentagon Port LLCSeries A$15.0M$198.7M3.96×
Amnic Inc.Series A$14.0M$198.2M3.95×
Intensivate IncSeries A$14.7M$190.3M3.79×
Ws Holdco, PbcSeries A$14.8M$188.2M3.75×
RxLive Inc. this companySeries A$10.1M$68.5M1.36×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$600K2018-06-21$3.3M$25.4M90%
Pre-Seed$850K2019-05-15$4.7M$36.0M90%
Seed$2.0M2020-07-31$10.0M$65.4M90%
Seed$1.6M2022-04-08$8.2M$24.1M90%
Series A$5.0M2022-04-08$23.0M$68.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$600K2018-06-21
    • First recorded raise — entered as Pre-Seed.
    • 9 investors on this round.
  2. Pre-Seed$850K2019-05-15
    • Raised 11 mo later, in step with the ~13 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 6 investors on this round.
  3. Seed$2.0M2020-07-31
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 24 investors on this round.
  4. Seed$1.6M2022-04-08
    • Raised again after 20 mo — slower than the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 8 investors on this round.
  5. Series A$5.0M2022-04-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.1× larger than the prior — scaling up.
    • 6 investors on this round.
Intelligence
2023 ~Q1
Modeled next raise · ~11mo cadence
$15.1M
Modeled next size est.range $9.8M$24.2M
3.1×
Last step-up
$2.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Loraine Daugherty1 other2019-05
SEAN MCNAMARA1 other2019-05
ELIOT HELLER2022-04
KRISTIN GRECO2020-07
MAR ENGELEN2022-04
MARK ENGELEN2018-06
Registry & provenance

RxLive Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1743807
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Kinedu, Inc.Other TechnologySeries A$10.1M$67.0Msame sector · same stage
Cased Inc.Other TechnologySeries A$10.3M$69.5Msame sector · same stage
Freedom! Family USA LtdOther TechnologySeries A$9.9M$68.7Msame sector · same stage
TopSchool, IncOther TechnologySeries A$10.5M$69.4Msame sector · same stage
Symbiosys Corp.Other TechnologySeries A$9.8M$67.5Msame sector · same stage
Measured Risk, Inc.Other TechnologySeries A$10.7M$68.2Msame sector · same stage
Partium, Inc.Other TechnologySeries A$10.8M$70.0Msame sector · same stage
Copilot Money, Inc.Other TechnologySeries A$10.8M$69.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
RxERP, Inc.Other TechnologySeed$14.4M88%
Compliant RX Inc.Other TechnologyPre-Seed$2.0M88%
Insight Rx, Inc.Other TechnologySeed$110.7M86%
RxCap, Inc.Other TechnologySeries B$156.6M85%
RPLAY Network Ltd.Other TechnologySeed$28.1M85%
RPost Communications LtdOther TechnologySeed$3.6M85%
RX Savings, LLCOther TechnologySeries B$561.5M85%
Rewindlive, Inc.Other TechnologyPre-Seed$37.9M84%
Frequently asked
How much funding has RxLive Inc. raised?
RxLive Inc. has raised approximately $10.1M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is RxLive Inc.'s estimated valuation?
Provath's modeled valuation for RxLive Inc. is approximately $68.5M (modeled range $6.7M–$247.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is RxLive Inc. at?
RxLive Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Apr 08.
What does RxLive Inc. do and where is it based?
RxLive Inc. operates in the Other Technology sector, based in ST. PETERSBURG.
Explore related

See where RxLive Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at RxLive Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.